Products for Research Use Only

RRx-001

CAT: 0804-HY-16438-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16438-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].
CAS Number
925206-65-1
Product Name Alternative
Nibrozetone
UNSPSC
12352005
Hazard Statement
H301, H311, H331, H341
Target
Apoptosis; CD47; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/RRx-001.html
Concentration
10mM
Purity
99.79
Solubility
DMSO : ≥ 100 mg/mL
Smiles
BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O
Molecular Formula
C5H6BrN3O5
Molecular Weight
268.02
Precautions
H301, H311, H331, H341
References & Citations
[1]Das DS, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30 (11) :2187-2197.|[2]Cabrales P, et al. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Transl Oncol. 2019 Apr;12 (4) :626-632.|[3]Yalcin O, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Plasmodium